Michelle Mcmurry-heath on biotech advocacy
From Advancing Science Through Biotech: With Dr. Michelle McMurry-Heath - Steve Forbes | Forbes · · Forbes
“Our role at BIO as serving as that voice, that platform for them, and that bridge to the broader cultural conversation about what science can do.”
On , Michelle Mcmurry-heath, Former President & CEO at BIO, spoke about biotech advocacy during Advancing Science Through Biotech: With Dr. Michelle McMurry-Heath - Steve Forbes | Forbes on Forbes.
About Michelle Mcmurry-heath
In a February 2021 interview with Steve Forbes, Dr. Michelle McMurry-Heath, then President and CEO of the Biotechnology Innovation Organization (BIO), discussed the role of the biotech industry during the COVID-19 pandemic. She described BIO's function as a "voice" and "platform" for scientists and a "bridge to the broader cultural conversation about what science can do." McMurry-Heath stated that "science is the social justice issue of our age," arguing that communities like the one she grew up in need access to clean water, nutritious food, clean air, and effective medical solutions. She criticized the U.S. vaccine distribution effort, saying "there is no excuse for where we find ourselves today" and noting that vaccines were being disposed of due to organizational failures. McMurry-Heath praised Operation Warp Speed for its foresight but emphasized the industry's collaborative efforts, including a BIO-facilitated platform that allowed companies to share resources. She called for a new approach to clinical trials, questioning why national trial networks are not more easily mobilized and why it remains difficult to include diverse patient populations. She also advocated for sustained flexibility at the FDA, stating that the agency's rapid-response approach during COVID should not be abandoned, but that this would require proper resourcing.